Hypomethylation-Triggered SERPINE1 (Serpin Family E Member 1) Exacerbates Polycystic Ovary Syndrome with Hyperandrogenism Induced by Circadian Disruption

Abstract

Polycystic ovary syndrome (PCOS), a prevalent cause of female infertility, arises from complex interactions between genetic and environmental factors, with hyperandrogenism serving as a core pathological feature. While growing evidence links circadian disruptions to the development of hyperandrogenism in PCOS, the underlying mechanism remains unclear. In this study, we employed DNA methylation profiling and RNA sequencing of ovarian granulosa cells from rats exposed to 8-week darkness, and identified serpin family E member 1 (SERPINE1) as a key player. SERPINE1 was significantly hypomethylated and upregulated in the dark group, correlating with elevated androgen levels. Mechanistically, using CRISPR–dCas9-based targeted methylation, we found that CpG hypomethylation near the SERPINE1 transcription start site drove its overexpression. Functional assays revealed that SERPINE1 suppression activated the PI3K/AKT signaling pathway, thereby enhancing CYP19A1 expression and enzymatic activity to facilitate androgen conversion in vitro. Moreover, treatment with the SERPINE1 inhibitor tiplaxtinin alleviated both reproductive and metabolic abnormalities in rat models treated with either dehydroepiandrosterone or exposed to darkness. These findings highlight SERPINE1's role in circadian disruption-induced hyperandrogenism and its potential as a methylome-based diagnostic biomarker for PCOS. Pharmacological inhibition of SERPINE1 emerges as a promising therapeutic strategy for hyperandrogenic PCOS.

Keywords

polycystic ovary syndrome / serpine1 (serpin family e member 1) / DNA methylation / circadian disruption exposure / hyperandrogenism

References

[1] D. A. Dumesic, S. E. Oberfield, E. Stener-Victorin, et al., “Scientific Statement on the Diagnostic Criteria, Epidemiology, Pathophysiology, and Molecular Genetics of Polycystic Ovary Syndrome,” Endocrine Reviews 36, no. 5 (2015): 487-525.

[2] W. A. March, V. M. Moore, K. J. Willson, et al., “The Prevalence of Polycystic Ovary Syndrome in a Community Sample Assessed Under Contrasting Diagnostic Criteria,” Human Reproduction 25, no. 2 (2010): 544-551.

[3] S. Risal, C. Li, Q. Luo, et al., “Transgenerational Transmission of Reproductive and Metabolic Dysfunction in the Male Progeny of Polycystic Ovary Syndrome,” Cell Rep Med 4, no. 5 (2023): 101035.

[4] L. J. Webber, S. Stubbs, J. Stark, et al., “Formation and Early Development of Follicles in the Polycystic Ovary,” Lancet 362, no. 9389 (2003): 1017-1021.

[5] S. Risal, Y. Pei, H. Lu, et al., “Prenatal Androgen Exposure and Transgenerational Susceptibility to Polycystic Ovary Syndrome,” Nature Medicine 25, no. 12 (2019): 1894-1904.

[6] B. S. Johnson, M. B. Krishna, R. A. Padmanabhan, et al., “Derailed Peripheral Circadian Genes in Polycystic Ovary Syndrome Patients Alters Peripheral Conversion of Androgens Synthesis,” Human Reproduction 37, no. 8 (2022): 1835-1855.

[7] F. Wang, N. Xie, Y. Wu, et al., “Association Between Circadian Rhythm Disruption and Polycystic Ovary Syndrome,” Fertility and Sterility 115, no. 3 (2021): 771-781.

[8] L. Barrea, L. Verde, C. Vetrani, et al., “Evening Chronotype Is Associated With Hormonal and Metabolic Disorders in Polycystic Ovary Syndrome,” Journal of Pineal Research 74, no. 2 (2023): e12844.

[9] G. Franik, K. Krysta, P. Madej, et al., “Sleep Disturbances in Women With Polycystic Ovary Syndrome,” Gynecological Endocrinology 32, no. 12 (2016): 1014-1017.

[10] S. L. Simon, L. McWhirter, B. C. Diniz, et al., “Morning Circadian Misalignment Is Associated with Insulin Resistance in Girls with Obesity and Polycystic Ovarian Syndrome,” Journal of Clinical Endocrinology and Metabolism 104, no. 8 (2019): 3525-3534.

[11] W. Chu, S. Li, X. Geng, et al., “Long-term Environmental Exposure of Darkness Induces Hyperandrogenism in PCOS via Melatonin Receptor 1A and Aromatase Reduction,” Frontiers in Cell and Developmental Biology 10 (2022): 954186.

[12] S. Li, J. Zhai, W. Chu, et al., “Altered Circadian Clock as a Novel Therapeutic Target for Constant Darkness-induced Insulin Resistance and Hyperandrogenism of Polycystic Ovary Syndrome,” Transl Res 219 (2020): 13-29.

[13] X. Geng, J. Zhao, J. Huang, et al., “lnc-MAP3K13-7:1 Inhibits Ovarian GC Proliferation in PCOS via DNMT1 Downregulation-Mediated CDKN1A Promoter Hypomethylation,” Molecular Therapy 29, no. 3 (2021): 1279-1293.

[14] D. Hiam, D. Simar, R. Laker, et al., “Epigenetic Reprogramming of Immune Cells in Women with PCOS Impact Genes Controlling Reproductive Function,” Journal of Clinical Endocrinology and Metabolism 104, no. 12 (2019): 6155-6170.

[15] J. X. Pan, Y. J. Tan, F. F. Wang, et al., “Aberrant Expression and DNA Methylation of Lipid Metabolism Genes in PCOS: A New Insight Into Its Pathogenesis,” Clin Epigenetics 10 (2018): 6.

[16] M. Yagi, S. Kishigami, A. Tanaka, et al., “Derivation of Ground-state Female ES Cells Maintaining Gamete-derived DNA Methylation,” Nature 548, no. 7666 (2017): 224-227.

[17] Y. Ye, A. Vattai, X. Zhang, et al., “Role of Plasminogen Activator Inhibitor Type 1 in Pathologies of Female Reproductive Diseases,” International Journal of Molecular Sciences 18, no. 8 (2017).

[18] J. K. Devin, J. E. Johnson, M. Eren, et al., “Transgenic Overexpression of Plasminogen Activator Inhibitor-1 Promotes the Development of Polycystic Ovarian Changes in Female Mice,” Journal of Molecular Endocrinology 39, no. 1 (2007): 9-16.

[19] E. Koiou, K. Tziomalos, K. Dinas, et al., “Plasma Plasminogen Activator Inhibitor-1 Levels in the Different Phenotypes of the Polycystic Ovary Syndrome,” Endocrine Journal 59, no. 1 (2012): 21-29.

[20] L. Bai, W. Wang, Y. Xiang, et al., “Aberrant Elevation of GDF8 Impairs Granulosa Cell Glucose Metabolism via Upregulating SERPINE1 Expression in Patients With PCOS,” Mol Ther Nucleic Acids 23 (2021): 294-309.

[21] R. Chen, L. Xia, K. Tu, et al., “Longitudinal Personal DNA Methylome Dynamics in a human With a Chronic Condition,” Nature Medicine 24, no. 12 (2018): 1930-1939.

[22] P. Bhatti, Y. Zhang, X. Song, et al., “Nightshift Work and Genome-wide DNA Methylation,” Chronobiology International 32, no. 1 (2015): 103-112.

[23] S. Pereira, D. L. Cline, M. M. Glavas, S. D. Covey, and T. J. Kieffer, “Tissue-Specific Effects of Leptin on Glucose and Lipid Metabolism,” Endocrine Reviews 42, no. 1 (2021): 1-28.

[24] R. Spolski, P. Li, and W. J. Leonard, “Biology and Regulation of IL-2: From Molecular Mechanisms to human Therapy,” Nature Reviews Immunology 18, no. 10 (2018): 648-659.

[25] M. Shahid, K. Rehman, M. Akash, et al., “Genetic Polymorphism in Angiotensinogen and Its Association With Cardiometabolic Diseases,” Metabolites 12, no. 12 (2022).

[26] A. Taschereau, V. Desgagné, S. Faleschini, et al., “SERPINE1 DNA Methylation Levels Quantified in Blood Cells at Five Years of Age Are Associated With Adiposity and Plasma PAI-1 Levels at Five Years of Age,” International Journal of Molecular Sciences 23, no. 19 (2022).

[27] A. K. Ghosh and D. E. Vaughan, “PAI-1 in Tissue Fibrosis,” Journal of Cellular Physiology 227, no. 2 (2012): 493-507.

[28] E. Koiou, K. Tziomalos, I. Katsikis, et al., “Disparate Effects of Pharmacotherapy on Plasma Plasminogen Activator Inhibitor-1 Levels in Women With the Polycystic Ovary Syndrome,” Hormones (Athens) 12, no. 4 (2013): 559-566.

[29] I. Tarkun, Z. Cantürk, B. C. Arslan, E. Türemen, and P. Tarkun, “The Plasminogen Activator System in Young and Lean Women With Polycystic Ovary Syndrome,” Endocrine Journal 51, no. 5 (2004): 467-472.

[30] M. T. Sellix, Z. C. Murphy, and M. Menaker, “Excess Androgen During Puberty Disrupts Circadian Organization in Female Rats,” Endocrinology 154, no. 4 (2013): 1636-1647.

[31] S. Roy, A. Abudu, I. Salinas, et al., “Androgen-mediated Perturbation of the Hepatic Circadian System through Epigenetic Modulation Promotes NAFLD in PCOS Mice,” Endocrinology 163, no. 10 (2022): bqac127.

[32] M. M. Suzuki and A. Bird, “DNA Methylation Landscapes: Provocative Insights From Epigenomics,” Nature Reviews Genetics 9, no. 6 (2008): 465-476.

[33] A. Azzi, R. Dallmann, A. Casserly, et al., “Circadian Behavior Is Light-reprogrammed by Plastic DNA Methylation,” Nature Neuroscience 17, no. 3 (2014): 377-382.

[34] M. Yonis, A. Haim, and A. E. Zubidat, “Altered Metabolic and Hormonal Responses in Male Rats Exposed to Acute Bright Light-at-night Associated With Global DNA Hypo-methylation,” Journal of Photochemistry and Photobiology B Biology 194 (2019): 107-118.

[35] Y. Zeng, Z. Zhang, S. Liang, et al., “Paternal Sleep Deprivation Induces Metabolic Perturbations in Male Offspring via Altered LRP5 DNA Methylation of Pancreatic Islets,” Journal of Pineal Research 74, no. 4 (2023): e12863.

[36] P. Sagvekar, P. Kumar, V. Mangoli, S. Desai, and S. Mukherjee, “DNA Methylome Profiling of Granulosa Cells Reveals Altered Methylation in Genes Regulating Vital Ovarian Functions in Polycystic Ovary Syndrome,” Clin Epigenetics 11, no. 1 (2019): 61.

[37] E. Makrinou, A. W. Drong, G. Christopoulos, et al., “Genome-wide Methylation Profiling in Granulosa Lutein Cells of Women With Polycystic Ovary Syndrome (PCOS),” Molecular and Cellular Endocrinology 500 (2020): 110611.

[38] M. Li, C. Zhu, Y. Xue, et al., “A DNA Methylation Signature for the Prediction of Tumour Recurrence in Stage II Colorectal Cancer,” British Journal of Cancer 128, no. 9 (2023): 1681-1689.

[39] K. Oishi, “Plasminogen Activator Inhibitor-1 and the Circadian Clock in Metabolic Disorders,” Clinical and Experimental Hypertension 31, no. 3 (2009): 208-219.

[40] A. Rouch, C. Vanucci-Bacqué, F. Bedos-Belval, and M. Baltas, “Small Molecules Inhibitors of Plasminogen Activator Inhibitor-1 - an Overview,” European Journal of Medicinal Chemistry 92 (2015): 619-636.

[41] A. J. Lucking, A. Visvanathan, H. Philippou, et al., “Effect of the Small Molecule Plasminogen Activator Inhibitor-1 (PAI-1) Inhibitor, PAI-749, in Clinical Models of Fibrinolysis,” Journal of Thrombosis and Haemostasis 8, no. 6 (2010): 1333-1339.

[42] W. Ruan, X. Yuan, and H. K. Eltzschig, “Circadian Rhythm as a Therapeutic Target,” Nat Rev Drug Discovery 20, no. 4 (2021): 287-307.

[43] R. Refinetti and G. J. Kenagy, “Diurnally Active Rodents for Laboratory Research,” Laboratory Animals 52, no. 6 (2018): 577-587.

[44] P. Qiu, J. Jiang, Z. Liu, et al., “BMAL1 knockout Macaque Monkeys Display Reduced Sleep and Psychiatric Disorders,” National Science Review 6, no. 1 (2019): 87-100.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.